Literature DB >> 26028481

MUTZ-3 derived Langerhans cells in human skin equivalents show differential migration and phenotypic plasticity after allergen or irritant exposure.

Ilona J Kosten1, Sander W Spiekstra1, Tanja D de Gruijl2, Susan Gibbs3.   

Abstract

After allergen or irritant exposure, Langerhans cells (LC) undergo phenotypic changes and exit the epidermis. In this study we describe the unique ability of MUTZ-3 derived Langerhans cells (MUTZ-LC) to display similar phenotypic plasticity as their primary counterparts when incorporated into a physiologically relevant full-thickness skin equivalent model (SE-LC). We describe differences and similarities in the mechanisms regulating LC migration and plasticity upon allergen or irritant exposure. The skin equivalent consisted of a reconstructed epidermis containing primary differentiated keratinocytes and CD1a(+) MUTZ-LC on a primary fibroblast-populated dermis. Skin equivalents were exposed to a panel of allergens and irritants. Topical exposure to sub-toxic concentrations of allergens (nickel sulfate, resorcinol, cinnamaldehyde) and irritants (Triton X-100, SDS, Tween 80) resulted in LC migration out of the epidermis and into the dermis. Neutralizing antibody to CXCL12 blocked allergen-induced migration, whereas anti-CCL5 blocked irritant-induced migration. In contrast to allergen exposure, irritant exposure resulted in cells within the dermis becoming CD1a(-)/CD14(+)/CD68(+) which is characteristic of a phenotypic switch of MUTZ-LC to a macrophage-like cell in the dermis. This phenotypic switch was blocked with anti-IL-10. Mechanisms previously identified as being involved in LC activation and migration in native human skin could thus be reproduced in the in vitro constructed skin equivalent model containing functional LC. This model therefore provides a unique and relevant research tool to study human LC biology in situ under controlled in vitro conditions, and will provide a powerful tool for hazard identification, testing novel therapeutics and identifying new drug targets.
Copyright © 2015. Published by Elsevier Inc.

Entities:  

Keywords:  Allergen; Chemokine; Irritant; Langerhans cell; Macrophage; Skin equivalent

Mesh:

Substances:

Year:  2015        PMID: 26028481     DOI: 10.1016/j.taap.2015.05.017

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  26 in total

Review 1.  Biology-inspired microphysiological system approaches to solve the prediction dilemma of substance testing.

Authors:  Uwe Marx; Tommy B Andersson; Anthony Bahinski; Mario Beilmann; Sonja Beken; Flemming R Cassee; Murat Cirit; Mardas Daneshian; Susan Fitzpatrick; Olivier Frey; Claudia Gaertner; Christoph Giese; Linda Griffith; Thomas Hartung; Minne B Heringa; Julia Hoeng; Wim H de Jong; Hajime Kojima; Jochen Kuehnl; Marcel Leist; Andreas Luch; Ilka Maschmeyer; Dmitry Sakharov; Adrienne J A M Sips; Thomas Steger-Hartmann; Danilo A Tagle; Alexander Tonevitsky; Tewes Tralau; Sergej Tsyb; Anja van de Stolpe; Rob Vandebriel; Paul Vulto; Jufeng Wang; Joachim Wiest; Marleen Rodenburg; Adrian Roth
Journal:  ALTEX       Date:  2016-05-15       Impact factor: 6.043

Review 2.  [Use of 2D and 3D cell cultures in dermatology].

Authors:  J Zeitvogel; T Werfel
Journal:  Hautarzt       Date:  2020-02       Impact factor: 0.751

3.  An epithelial organoid model with Langerhans cells for assessing virus-host interactions.

Authors:  Robert Jackson; Statton Eade; Ingeborg Zehbe
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2019-05-27       Impact factor: 6.237

Review 4.  Bioengineered Wound Healing Skin Models: The Role of Immune Response and Endogenous ECM to Fully Replicate the Dynamic of Scar Tissue Formation In Vitro.

Authors:  Francesco Urciuolo; Roberta Passariello; Giorgia Imparato; Costantino Casale; Paolo Antonio Netti
Journal:  Bioengineering (Basel)       Date:  2022-05-27

5.  Progress on Reconstructed Human Skin Models for Allergy Research and Identifying Contact Sensitizers.

Authors:  Charlotte Rodrigues Neves; Susan Gibbs
Journal:  Curr Top Microbiol Immunol       Date:  2021       Impact factor: 4.291

6.  Development of a Full-Thickness Human Gingiva Equivalent Constructed from Immortalized Keratinocytes and Fibroblasts.

Authors:  Jeroen K Buskermolen; Christianne M A Reijnders; Sander W Spiekstra; Thorsten Steinberg; Cornelis J Kleverlaan; Albert J Feilzer; Astrid D Bakker; Susan Gibbs
Journal:  Tissue Eng Part C Methods       Date:  2016-08       Impact factor: 3.056

Review 7.  Innovative organotypic in vitro models for safety assessment: aligning with regulatory requirements and understanding models of the heart, skin, and liver as paradigms.

Authors:  Chris S Pridgeon; Constanze Schlott; Min Wei Wong; Minne B Heringa; Tobias Heckel; Joe Leedale; Laurence Launay; Vitalina Gryshkova; Stefan Przyborski; Rachel N Bearon; Emma L Wilkinson; Tahera Ansari; John Greenman; Delilah F G Hendriks; Sue Gibbs; James Sidaway; Rowena L Sison-Young; Paul Walker; Mike J Cross; B Kevin Park; Chris E P Goldring
Journal:  Arch Toxicol       Date:  2018-01-23       Impact factor: 5.153

8.  Comparative phenotypic and functional analysis of migratory dendritic cell subsets from human oral mucosa and skin.

Authors:  Ilona Jennifer Kosten; Rieneke van de Ven; Maria Thon; Susan Gibbs; Tanja D de Gruijl
Journal:  PLoS One       Date:  2017-07-13       Impact factor: 3.240

Review 9.  Progress and Future Prospectives in Skin-on-Chip Development with Emphasis on the use of Different Cell Types and Technical Challenges.

Authors:  Lenie J van den Broek; Lambert I J C Bergers; Christianne M A Reijnders; Susan Gibbs
Journal:  Stem Cell Rev Rep       Date:  2017-06       Impact factor: 5.739

10.  Patch test-relevant concentrations of metal salts cause localized cytotoxicity, including apoptosis, in skin ex vivo.

Authors:  Yan Zhang; Niels P J de Graaf; Rosalien Veldhuizen; Sanne Roffel; Sander W Spiekstra; Thomas Rustemeyer; Cees J Kleverlaan; Albert J Feilzer; Hetty Bontkes; Dongmei Deng; Susan Gibbs
Journal:  Contact Dermatitis       Date:  2021-08-15       Impact factor: 6.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.